BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,221

Employees3,221

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,221

Employees3,221

BMRN Key Statistics

Market cap

10.56B

Market cap10.56B

Price-Earnings ratio

29.96

Price-Earnings ratio29.96

Dividend yield

—

Dividend yield—

Average volume

1.43M

Average volume1.43M

High today

$55.15

High today$55.15

Low today

$53.45

Low today$53.45

Open price

$53.66

Open price$53.66

Volume

978.07K

Volume978.07K

52 Week high

$66.28

52 Week high$66.28

52 Week low

$50.76

52 Week low$50.76

Stock Snapshot

With a market cap of 10.56B, BioMarin(BMRN) trades at $54.91. The stock has a price-to-earnings ratio of 29.96.

During the trading session on 2026-05-04, BioMarin(BMRN) shares reached a daily high of $55.15 and a low of $53.45. At a current price of $54.91, the stock is +2.7% higher than the low and still -0.4% under the high.

Trading activity shows a volume of 978.07K, compared to an average daily volume of 1.43M.

The stock's 52-week range extends from a low of $50.76 to a high of $66.28.

BMRN News

Simply Wall St 12h

How Investors Are Reacting To BioMarin VOXZOGO Data Showing Benefits Beyond Height in Achondroplasia

In early May 2026, BioMarin Pharmaceutical reported new VOXZOGO (vosoritide) data in children with achondroplasia, showing benefits beyond height, including imp...

TipRanks 23h

BioMarin announces new research from studies of Voxzogo

BioMarin (BMRN) Pharmaceutical announced new research from studies of Voxzogo in children with achondroplasia demonstrating positive impact on important health...

Simply Wall St 3d

Assessing BioMarin Valuation As Shares Show Recent Weakness And DCF Signals Deep Discount

Advertisement Recent performance snapshot BioMarin Pharmaceutical (BMRN) has drawn fresh attention after recent trading, with the share price at US$54.06 and...

Analyst ratings

81%

of 27 ratings

Buy

81.5%

Hold

18.5%

Sell

More BMRN News

Simply Wall St 4d

BioMarin Amicus Deal Expands Rare Disease Reach And Adds Kidney Asset

BioMarin Pharmaceutical (NasdaqGS:BMRN) has completed its acquisition of Amicus Therapeutics. The deal adds two approved lysosomal storage disease treatments t...

Simply Wall St 5d

BioMarin Closes Amicus Deal As FOLD Delists And Indices Adjust

BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, previously listed as NasdaqGM:FOLD. Following the transaction, Amicus has been de...

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.